Abstract
There is a wide variation in cancer incidence in humans, which, in part, has been attributed to metabolic factors of carcinogens and genetic polymorphisms in drug metabolising enzymes and drug transporters. Drug metabolising enzymes are responsible for the initial activation of many (pro)carcinogens, such as polycyclic aromatic hydrocarbons (PAH), to biologically reactive metabolites. Besides, detoxifying enzymes are responsible for the inactivation of these active carcinogens and deficiency of these enzymes may result in an increase of cancer risk in exposed individuals. Another factor influencing interindividual variability in cancer incidence is the transporters, which are responsible for the excretion of carcinogens. A high number of polymorphisms have been described in drug metabolising enzymes and drug transporter genes. These polymorphisms might influence the activity of metabolising enzymes and drug transporters and thereby affect cancer risk. This review will focus on the role of genetic polymorphisms of selected drug metabolising enzymes (CYP1A1, 2C9, 2C19, 3A4, 3A5, UGT1A1, GSTM1, GSTP1, GSTT1, SULT1A1, NAT1 and NAT2) and ABCtransporters (P-gp and BRCP) in relation to cancer risk.
Keywords: Polymorphisms, drug-metabolising enzymes, drug transporters, cancer risk
Current Cancer Therapy Reviews
Title: Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Volume: 2 Issue: 2
Author(s): Tessa M. Bosch, Irma Meijerman, Jos H. Beijnen and Jan H.M. Schellens
Affiliation:
Keywords: Polymorphisms, drug-metabolising enzymes, drug transporters, cancer risk
Abstract: There is a wide variation in cancer incidence in humans, which, in part, has been attributed to metabolic factors of carcinogens and genetic polymorphisms in drug metabolising enzymes and drug transporters. Drug metabolising enzymes are responsible for the initial activation of many (pro)carcinogens, such as polycyclic aromatic hydrocarbons (PAH), to biologically reactive metabolites. Besides, detoxifying enzymes are responsible for the inactivation of these active carcinogens and deficiency of these enzymes may result in an increase of cancer risk in exposed individuals. Another factor influencing interindividual variability in cancer incidence is the transporters, which are responsible for the excretion of carcinogens. A high number of polymorphisms have been described in drug metabolising enzymes and drug transporter genes. These polymorphisms might influence the activity of metabolising enzymes and drug transporters and thereby affect cancer risk. This review will focus on the role of genetic polymorphisms of selected drug metabolising enzymes (CYP1A1, 2C9, 2C19, 3A4, 3A5, UGT1A1, GSTM1, GSTP1, GSTT1, SULT1A1, NAT1 and NAT2) and ABCtransporters (P-gp and BRCP) in relation to cancer risk.
Export Options
About this article
Cite this article as:
Bosch M. Tessa, Meijerman Irma, Beijnen H. Jos and Schellens H.M. Jan, Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk, Current Cancer Therapy Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339406776872825
DOI https://dx.doi.org/10.2174/157339406776872825 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diversity of Anticancer and Antimicrobial Compounds from Lichens and Lichen-derived Fungi: A Systematic Review (1985-2017)
Current Organic Chemistry Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics
Reviews on Recent Clinical Trials Vascular effects of flavonoids
Current Medicinal Chemistry Tailoring NO Donors Metallopharmaceuticals: Ruthenium Nitrosyl Ammines and Aliphatic Tetraazamacrocycles
Current Medicinal Chemistry Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Epidemiology and Natural History of Patients with NAFLD
Current Pharmaceutical Design Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Current Genomics Cytotoxicity of a Vanadyl(IV) Complex with a Multidentate Oxygen Donor in Osteoblast Cell Lines in Culture
Medicinal Chemistry Heme Oxygenase-1 in Lung Disease
Current Drug Targets Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
Current Medicinal Chemistry - Anti-Cancer Agents Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research Neuregulin Signaling in Pieces-Evolution of the Gene Family
Current Pharmaceutical Design Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors
Current Cancer Drug Targets Exfoliated Epithelial Cells: A Non-Invasive way to Evaluate the Physiological State of Gastrointestinal Epithelium
Recent Patents on Biomedical Engineering (Discontinued) Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy